MCID: OVR012
MIFTS: 56

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 55 6 15 17 72
Serous Cystadenoma 12 17
Cystadenoma, Serous 72
Cystadenoma Serous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 50 C7978
UMLS 72 C0206709 C0279663

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as serous cystadenoma, is related to adenocarcinoma and endocrine gland cancer. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Cisplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and spleen, and related phenotypes are cellular and cardiovascular system

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.9 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
2 endocrine gland cancer 30.9 TP53 HRAS ERBB2 AKT1
3 fallopian tube carcinoma 30.9 TP53 PGR ERBB2
4 in situ carcinoma 30.9 TP53 PGR ERBB2
5 differentiated thyroid carcinoma 30.5 TP53 NRAS HRAS BRAF BCL2
6 lung cancer susceptibility 3 30.0 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
7 serous cystadenocarcinoma 29.4 ZNF217 USP2 UBE4A TP53 PIK3CA PGR
8 cystadenocarcinoma 29.4 ZNF217 USP2 UBE4A TP53 PIK3CA PGR
9 ovarian cancer 28.9 TP53 PIK3CA PGR MUC16 FSHR ERBB2
10 endometrial cancer 28.8 TP53 PIK3CA PGR MUC16 HRAS ERBB2
11 pancreatic serous cystadenoma 12.8
12 serous or mucinous cystadenoma of childhood 11.4
13 giant congenital nevus 10.8 NRAS HRAS
14 nevus of ota 10.8 TP53 BRAF
15 adult hepatocellular carcinoma 10.8 TP53 PIK3CA
16 endometrium carcinoma in situ 10.8 TP53 PGR
17 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
18 epithelial-myoepithelial carcinoma 10.7 TP53 HRAS FBXW7
19 erdheim-chester disease 10.7 PIK3CA NRAS BRAF
20 breast squamous cell carcinoma 10.7 TP53 PIK3CA ERBB2
21 malignant spiradenoma 10.7 TP53 PIK3CA
22 prostate adenoid cystic carcinoma 10.7 PIK3CA LRRC56 HRAS
23 liver angiosarcoma 10.7 TP53 NRAS HRAS
24 apocrine adenoma 10.7 PIK3CA HRAS
25 breast apocrine carcinoma 10.7 PGR ERBB2
26 scirrhous adenocarcinoma 10.7 PGR ERBB2
27 brain stem glioma 10.7 TP53 PIK3CA BRAF
28 glassy cell carcinoma of the cervix 10.7 PGR ERBB2
29 nevus, epidermal 10.7 PIK3CA NRAS HRAS
30 rare adenocarcinoma of the breast 10.7 TP53 PIK3CA AKT1
31 adenosquamous lung carcinoma 10.7 PIK3CA HRAS ERBB2
32 ovarian clear cell carcinoma 10.7 ZNF217 TP53 PIK3CA
33 skin melanoma 10.7 TP53 NRAS BRAF
34 adenoma 10.7
35 pulmonic stenosis 10.7 LRRC56 HRAS BRAF
36 uterine corpus serous adenocarcinoma 10.6 TP53 PIK3CA FBXW7 ERBB2
37 microglandular adenosis 10.6 TP53 PGR ERBB2
38 meningeal melanomatosis 10.6 TP53 NRAS HRAS B2M
39 intracystic papillary adenoma 10.6 PGR ERBB2
40 benign struma ovarii 10.6 NRAS HRAS
41 colorectal adenocarcinoma 10.6 TP53 HRAS BRAF
42 thoracic benign neoplasm 10.6 TP53 PGR ERBB2
43 breast benign neoplasm 10.6 TP53 PGR ERBB2
44 ovarian cystadenocarcinoma 10.6 ZNF217 UBE4A HRAS
45 bile duct adenocarcinoma 10.6 TP53 HRAS AKT1
46 prostate squamous cell carcinoma 10.6 TP53 LRRC56 HRAS B2M
47 pre-malignant neoplasm 10.6 TP53 PGR ERBB2
48 histiocytic sarcoma 10.6 BRAF BCL2
49 breast metaplastic carcinoma 10.6 PGR ERBB2
50 autonomic nervous system neoplasm 10.6 TP53 NRAS AKT1

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
2 cardiovascular system MP:0005385 10.37 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
3 behavior/neurological MP:0005386 10.35 AKT1 BCL2 BRAF ERBB2 FSHR HRAS
4 endocrine/exocrine gland MP:0005379 10.34 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
5 homeostasis/metabolism MP:0005376 10.3 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
6 growth/size/body region MP:0005378 10.26 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
7 integument MP:0010771 10.25 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
8 mortality/aging MP:0010768 10.25 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
9 embryo MP:0005380 10.21 AKT1 BCL2 BRAF ERBB2 FBXW7 NANOG
10 digestive/alimentary MP:0005381 10.13 B2M BCL2 BRAF ERBB2 FBXW7 HRAS
11 neoplasm MP:0002006 10.1 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
12 craniofacial MP:0005382 10.08 BCL2 BRAF ERBB2 FBXW7 HRAS NRAS
13 nervous system MP:0003631 10 AKT1 B2M BCL2 BRAF ERBB2 FBXW7
14 muscle MP:0005369 9.97 AKT1 BCL2 BRAF ERBB2 PGR PIK3CA
15 reproductive system MP:0005389 9.73 AKT1 B2M BCL2 BRAF ERBB2 FSHR
16 no phenotypic analysis MP:0003012 9.7 HRAS NANOG NRAS PGR PIK3CA TP53
17 skeleton MP:0005390 9.32 AKT1 BRAF ERBB2 FSHR HRAS NRAS

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7 Angiogenesis Inhibitors Phase 3
8 Angiogenesis Modulating Agents Phase 3
9 Antineoplastic Agents, Immunological Phase 3
10 Tubulin Modulators Phase 2, Phase 3
11 Antimitotic Agents Phase 2, Phase 3
12 Topoisomerase Inhibitors Phase 3
13 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
14 Albumin-Bound Paclitaxel Phase 2, Phase 3
15 Alkylating Agents Phase 3
16 Immunosuppressive Agents Phase 3
17 Immunologic Factors Phase 3
18 Antirheumatic Agents Phase 3
19 Antineoplastic Agents, Alkylating Phase 3
20 Analgesics Phase 3
21 Peripheral Nervous System Agents Phase 3
22
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
23
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
24
Lenograstim Approved, Investigational Phase 2 135968-09-1
25
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
26
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
27
Liposomal doxorubicin Phase 2 31703
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 topoisomerase I inhibitors Phase 2
31 Protein Kinase Inhibitors Phase 1, Phase 2
32
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
33 Antimetabolites Phase 2
34 Antimetabolites, Antineoplastic Phase 2
35
Pancrelipase Approved, Investigational Phase 1 53608-75-6
36
Melphalan Approved Phase 1 148-82-3 460612 4053
37
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
38
Iodine Approved, Investigational Phase 1 7553-56-2 807
39
Etoposide Approved Phase 1 33419-42-0 36462
40 pancreatin Phase 1
41 Antibodies Phase 1
42 Immunoglobulins Phase 1
43 Immunotoxins Phase 1
44 Antibodies, Monoclonal Phase 1
45 Vaccines Phase 1
46 Liver Extracts Phase 1
47 Etoposide phosphate Phase 1
48 Gastrointestinal Agents
49 Pharmaceutical Solutions
50 Cola

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study Unknown status NCT02097446 Phase 3
2 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
4 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
5 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
8 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
9 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
10 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
11 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
12 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
13 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
14 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
15 A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum Terminated NCT00354601 Phase 2 capecitabine;docetaxel
16 A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
17 Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary Withdrawn NCT00003865 Phase 2 toremifene
18 A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
19 A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
20 A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer Completed NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
21 Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing Completed NCT00066651 Phase 1
22 A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
23 A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer Completed NCT00002977 Phase 1 melphalan;thiotepa
24 A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
25 Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Completed NCT00408590 Phase 1
26 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
27 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
28 A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
29 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
30 A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
31 A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas Unknown status NCT02523170
32 Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis Unknown status NCT00238342
33 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Unknown status NCT00897039
34 Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors. Recruiting NCT03305146
35 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Active, not recruiting NCT03884179
36 Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions Terminated NCT02494388
37 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514
38 A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

41
Pancreas, Ovary, Spleen, T Cells, Liver, Testes, Bone Marrow

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show top 50) (show all 895)
# Title Authors PMID Year
1
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. 9 38
17309670 2007
2
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. 9 38
17160949 2006
3
Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease. 9 38
14627339 2003
4
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 9 38
1506732 1992
5
Bilateral ovarian fibromas with concomitant unilateral serous cystadenoma: a rare case with review of literature. 38
31303118 2019
6
Cytohistological diagnosis of pancreatic serous cystadenoma: a multimodal approach. 38
31235542 2019
7
Etiologic Distribution of Pancreatic Cystic Lesions Identified on Computed Tomography/Magnetic Resonance Imaging. 38
31404022 2019
8
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. 38
31406154 2019
9
[Microcystic serous cystadenoma: An uncommon neoplasm of pancreas. Report of two cases]. 38
30711334 2019
10
Coexisting pancreatic serous cystadenoma and pancreatic ductal adenocarcinoma: A cytological-pathologic correlation with literature review. 38
31382079 2019
11
Giant serous cystadenoma of the pancreas appearing sonographically as a remote pararenal mass. 38
30907433 2019
12
Serous Cystadenoma of the Pancreas With Complex Florid Papillary Architecture: A Case Report and Review of the Literature. 38
31187681 2019
13
miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. 38
31068580 2019
14
MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS. 38
31322508 2019
15
Macrocystic serous cystadenoma of the pancreas. 38
31023580 2019
16
Giant Primary Retroperitoneal Serous Cystadenoma: A Rare Entity Mimicking Multiple Neoplastic and Nonneoplastic Processes. 38
31017452 2019
17
The honeycomb pattern of pancreatic serous cystadenoma. 38
30288583 2019
18
TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. 38
30542790 2019
19
Evaluation of histo-pathogical patterns of ovarian masses in relation to age in Rawalpindi-Islamabad region - Lab Research. 38
30804603 2019
20
Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining. 38
30430389 2019
21
Tumor growth rate of pancreatic serous cystadenomas: Endosonographic follow-up with volume measurement to predict cyst enlargement. 38
30503637 2019
22
LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway. 38
31384176 2019
23
Discrimination of Pancreatic Serous Cystadenomas From Mucinous Cystadenomas With CT Textural Features: Based on Machine Learning. 38
31245294 2019
24
Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh. 38
30983807 2019
25
A Rare Case of Ovarian Serous Borderline Tumor with Brain Metastasis. 38
31240144 2019
26
Transcriptomic study of the mechanism of anoikis resistance in head and neck squamous carcinoma. 38
31198634 2019
27
[Pseudo-Meigs syndrome secondary to ovarian serous cystadenoma]. 38
31303956 2019
28
Dilemma of the giant abdominal cyst. 38
30635316 2019
29
Giant symptomatic serous cystadenoma mimicking carcinoma: A case report and literature review. 38
31212091 2019
30
Incidental Gynecologic Tract Neoplasms in Women Undergoing Anterior Pelvic Exenteration for Urothelial Carcinoma. 38
29257039 2019
31
Serous Pancreatic Cystadenoma with Compression of Wirsung's Duct. 38
29736662 2019
32
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. 38
30446011 2018
33
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. 38
30097905 2018
34
Needle-based confocal laser endomicroscopy of pancreatic cystic lesions: a prospective multicenter validation study in patients with definite diagnosis. 38
30347425 2018
35
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. 38
30287996 2018
36
Atypical Solid Serous Cystadenoma of the Pancreas. 38
30454515 2018
37
A left-sided cystic pancreatic incidentaloma with sigmoid colon adenocarcinoma: a case report. 38
30157943 2018
38
Umbilical Lesions: Clinicopathologic Features of 99 Tumors. 38
29484912 2018
39
[Diagnosis and treatment experience of 161 cases of pancreatic serous cystic neoplasm in single center and analysis of cause of preoperation misjudgement]. 38
30107701 2018
40
The Role of Endoscopic Ultrasound in the Diagnosis of Cystic Lesions of the Pancreas. 38
30140684 2018
41
Moray micro forceps biopsy improves the diagnosis of specific pancreatic cysts. 38
29660844 2018
42
Incidence and reasons of pancreatic resection in patients with asymptomatic serous cystadenoma. 38
29903633 2018
43
MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells. 38
29899543 2018
44
Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa? 38
28700429 2018
45
Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions (with video). 38
29309781 2018
46
Middle segment pancreatectomy for a solid serous cystadenoma diagnosed by MRCP and review of the literature: A case report. 38
29725534 2018
47
Ultrasound-guided follicle aspiration at time of laparotomy in a patient with Mayer-Rokitansky-Küster-Hauser syndrome. 38
29778392 2018
48
Inspissated cyst fluid in endoscopic ultrasound-guided fine needle aspiration of pancreatic cysts. 38
29476610 2018
49
[Simple mucinous cyst of the pancreas: Case-report and literature review]. 38
29415811 2018
50
Conservative laparoscopic management of adnexal torsion based on a 17-year follow-up experience. 38
29486636 2018

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show top 50) (show all 225)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
4 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
5 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
6 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
7 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
8 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
9 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
10 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
11 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
13 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
14 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
15 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
16 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
17 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
18 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
19 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
20 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
21 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
22 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
23 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
24 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
25 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
26 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
27 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
28 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
29 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
30 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
31 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
32 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
33 TP53 NM_000546.5(TP53): c.817C> A (p.Arg273Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913343 17:7577121-7577121 17:7673803-7673803
34 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
35 NRAS NM_002524.5(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
36 TP53 NM_000546.5(TP53): c.730G> A (p.Gly244Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519989 17:7577551-7577551 17:7674233-7674233
37 TP53 NM_000546.5(TP53): c.809T> C (p.Phe270Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519986 17:7577129-7577129 17:7673811-7673811
38 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
39 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs786202962 17:7578403-7578403 17:7675085-7675085
40 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 17:7577114-7577114 17:7673796-7673796
41 TP53 NM_000546.5(TP53): c.517G> A (p.Val173Met) single nucleotide variant Pathogenic/Likely pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
42 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
43 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 17:7577580-7577580 17:7674262-7674262
44 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
45 TP53 NM_000546.5(TP53): c.700T> C (p.Tyr234His) single nucleotide variant Pathogenic/Likely pathogenic rs864622237 17:7577581-7577581 17:7674263-7674263
46 TP53 NM_000546.5(TP53): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic/Likely pathogenic rs985033810 17:7577550-7577550 17:7674232-7674232
47 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
48 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
49 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
50 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 UBE4A TP53 PIK3CA NRAS NANOG MUC16
2
Show member pathways
13.81 PIK3CA NRAS MUC16 HRAS FBXW7 ERBB2
3
Show member pathways
13.63 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
4
Show member pathways
13.55 UBE4A TP53 PIK3CA NRAS HRAS FBXW7
5
Show member pathways
13.43 TP53 PIK3CA NRAS NANOG HRAS ERBB2
6
Show member pathways
13.3 TP53 NRAS HRAS ERBB2 BRAF BCL2
7
Show member pathways
13.12 PIK3CA PGR NRAS HRAS BCL2 AKT1
8
Show member pathways
13.1 TP53 NRAS NANOG HRAS BRAF AKT1
9
Show member pathways
13.08 TP53 PIK3CA NRAS HRAS ERBB2 BCL2
10
Show member pathways
13.06 TP53 PIK3CA NRAS HRAS BCL2 B2M
11
Show member pathways
13.04 TP53 PIK3CA NRAS HRAS BCL2 AKT1
12
Show member pathways
13.01 TP53 PIK3CA NRAS HRAS BRAF AKT1
13
Show member pathways
13 PIK3CA NRAS HRAS ERBB2 BRAF AKT1
14
Show member pathways
13 PIK3CA NRAS HRAS ERBB2 BRAF BCL2
15
Show member pathways
12.96 PIK3CA NRAS HRAS ERBB2 BRAF AKT1
16
Show member pathways
12.94 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
17
Show member pathways
12.91 TP53 PIK3CA NRAS HRAS BCL2 AKT1
18 12.89 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
19 12.87 TP53 NRAS HRAS ERBB2 BRAF AKT1
20
Show member pathways
12.83 TP53 PIK3CA NRAS HRAS ERBB2 AKT1
21
Show member pathways
12.82 PIK3CA NRAS HRAS BRAF AKT1
22
Show member pathways
12.78 TP53 NRAS HRAS BRAF BCL2 AKT1
23
Show member pathways
12.71 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
24
Show member pathways
12.69 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
25
Show member pathways
12.69 TP53 PIK3CA PGR NRAS HRAS ERBB2
26
Show member pathways
12.68 TP53 PIK3CA NRAS HRAS ERBB2 BCL2
27 12.64 TP53 PIK3CA NRAS HRAS ERBB2 BCL2
28
Show member pathways
12.63 PIK3CA NRAS HRAS AKT1
29
Show member pathways
12.59 PIK3CA NRAS HRAS ERBB2 BCL2 AKT1
30
Show member pathways
12.59 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
31
Show member pathways
12.54 PIK3CA NRAS HRAS AKT1
32
Show member pathways
12.53 NRAS HRAS BRAF BCL2 AKT1
33
Show member pathways
12.53 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
34
Show member pathways
12.51 TP53 PIK3CA HRAS AKT1
35
Show member pathways
12.51 PIK3CA NRAS HRAS BCL2 AKT1
36
Show member pathways
12.51 PIK3CA NRAS HRAS BRAF AKT1
37
Show member pathways
12.48 PIK3CA NRAS HRAS AKT1
38
Show member pathways
12.48 PIK3CA HRAS BRAF AKT1
39
Show member pathways
12.48 PIK3CA NRAS HRAS ERBB2 BRAF
40
Show member pathways
12.47 TP53 PIK3CA HRAS AKT1
41 12.46 TP53 PIK3CA NRAS HRAS AKT1
42
Show member pathways
12.44 PIK3CA PGR BRAF AKT1
43
Show member pathways
12.44 NRAS HRAS BRAF BCL2 AKT1
44
Show member pathways
12.44 TP53 PIK3CA NRAS HRAS ERBB2 BCL2
45
Show member pathways
12.41 PIK3CA HRAS ERBB2 AKT1
46
Show member pathways
12.41 PIK3CA NRAS HRAS AKT1
47 12.41 PIK3CA FSHR BRAF AKT1
48
Show member pathways
12.4 PIK3CA NRAS HRAS ERBB2 AKT1
49
Show member pathways
12.39 TP53 PIK3CA HRAS AKT1
50 12.38 TP53 PIK3CA NRAS HRAS

GO Terms for Ovarian Serous Cystadenocarcinoma

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 TP53 HRAS ERBB2 BRAF AKT1
2 negative regulation of gene expression GO:0010629 9.87 PGR HRAS FBXW7 AKT1
3 MAPK cascade GO:0000165 9.83 NRAS HRAS ERBB2 BRAF
4 cytokine-mediated signaling pathway GO:0019221 9.77 TP53 PIK3CA NANOG BCL2 AKT1
5 positive regulation of cell growth GO:0030307 9.73 ERBB2 BCL2 AKT1
6 negative regulation of neuron apoptotic process GO:0043524 9.71 PIK3CA HRAS BRAF BCL2
7 Ras protein signal transduction GO:0007265 9.69 TP53 NRAS HRAS
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 NRAS MUC16 HRAS
9 regulation of protein localization GO:0032880 9.63 FBXW7 BCL2 AKT1
10 negative regulation of macroautophagy GO:0016242 9.58 PIK3CA AKT1
11 regulation of mitochondrial membrane permeability GO:0046902 9.55 TP53 BCL2
12 anoikis GO:0043276 9.54 PIK3CA AKT1
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.5 PIK3CA ERBB2 AKT1
14 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 HRAS FSHR FBXW7 BRAF
15 circadian behavior GO:0048512 9.43 USP2 TP53
16 cell aging GO:0007569 9.43 TP53 HRAS BCL2
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.26 PIK3CA BRAF BCL2 AKT1
18 cell proliferation GO:0008283 8.8 TP53 BCL2 AKT1

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 ZNF217 USP2 USP14 UBE4A TP53 PIK3CA
2 nucleotide binding GO:0000166 9.56 NRAS HRAS ERBB2 BRAF
3 protein phosphatase binding GO:0019903 9.5 TP53 ERBB2 BCL2
4 protein phosphatase 2A binding GO:0051721 9.33 TP53 BCL2 AKT1
5 identical protein binding GO:0042802 9.28 USP2 TP53 PGR FBXW7 ERBB2 BRAF

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....